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Background: Honeybee venom is a complicated defensive toxin that has a wide range of pharmacologically active
compounds. Some of these compounds are useful for human therapeutics. There are two major forms of honeybee
venom used in pharmacological applications: manually (or reservoir disrupting) extracted glandular venom (GV),
and venom extracted through the use of electrical stimulation (ESV). A proteome comparison of these two venom
forms and an understanding of the phosphorylation status of ESV, are still very limited. Here, the proteomes of GV
and ESV were compared using both gel-based and gel-free proteomics approaches and the phosphoproteome of
ESV was determined through the use of TiO2 enrichment.
Results: Of the 43 proteins identified in GV, < 40% were venom toxins, and > 60% of the proteins were non-toxic proteins
resulting from contamination by gland tissue damage during extraction and bee death. Of the 17 proteins identified in ESV,
14 proteins (>80%) were venom toxic proteins and most of them were found in higher abundance than in GV. Moreover,
two novel proteins (dehydrogenase/reductase SDR family member 11-like and histone H2B.3-like) and three
novel phosphorylation sites (icarapin (S43), phospholipase A-2 (T145), and apamin (T23)) were identified.
Conclusions: Our data demonstrate that venom extracted manually is different from venom extracted using
ESV, and these differences may be important in their use as pharmacological agents. ESV may be more efficient
than GV as a potential pharmacological source because of its higher venom protein content, production
efficiency, and without the need to kill honeybee. The three newly identified phosphorylated venom proteins in
ESV may elicit a different immune response through the specific recognition of antigenic determinants. The two
novel venom proteins extend our proteome coverage of honeybee venom.
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Venom from social hymenoptera (wasps, bees, and ants)
is used as an effective and important chemical weapon
for the defense of individuals or of the colony. This can
be achieved by injection of very low concentrations of
venom into an enemy that reaches its bloodstream in a
few minutes [1]. Honeybee (Apis mellifera) venom is* Correspondence: apislijk@163.com
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reproduction in any medium, provided the ornow known to contain 12 proteins that are recognized
as allergens in humans by the International Union of
Immunological Societies [2]. The allergic response to
these proteins in a sting victim varies from swelling, red-
ness, pain, itching around the sting site, and potentially
life-threatening allergic effects, including anaphylactic
shock [3,4]. The biochemical composition of honeybee
venom has been reported to have a wide array of bio-
molecules, such as biogenic amines, peptides and pro-
teins [5]. In addition, honeybee venom has been well
documented for pharmaceutical purposes in treatment
of pathological conditions such as arthritis, neurodynia,his is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Recently, it has been discovered that melittin-loaded
nanoparticles can attenuate HIV-1 infectivity, demonstrat-
ing the promising potential of bee venom for treatment of
HIV [10]. Currently, several pharmaceutical formulations
using crude honeybee venom have been registered and are
available on the European and global markets, such as
Forapin, Germany; Virapin, Slovakia; Apiven, France;
Melivenon, Bulgaria; and Apifor, Russia [11].
Because bee venom is a human toxin, a comprehensive
characterization of its molecular composition, side ef-
fects, and toxicology is of paramount importance for the
development safe pharmaceutical formulations to satisfy
human demand. To further this goal, honeybee venom
has been intensively examined in the past [12-14]. Due
to its highly complex nature, bee venom has not been
fully characterized by previous methods. Recently devel-
oped techniques, namely mass spectrometry (MS), have
highly improved resolution and sensitivity, allowing the
identification of thousands of proteins or peptides using
a tiny amount of protein sample in a single run. A
comprehensive profiling of honeybee venom has been
achieved since 2005 using this robust MS platform
[15-18]. Although the venom proteome of the honey-
bee has been significantly extended, previous studies
have been performed using a singular proteomics ap-
proach such as either two dimensional electrophoresis
(2-DE or gel-based proteomics) or an MS run (gel-free
proteomics). Using only one technique may result in
an underestimate of the proteome; 2-DE based proteo-
mics may exclude proteins with extreme molecular
weights (<15 kDa or >200 kDa) [19], while MS-based pro-
teomics can mask the low abundance proteins [20]. How-
ever, a combination of gel-based and gel-free proteomics
has proven to be an efficient protocol to increase prote-
ome coverage of a biological sample [18,20].
At present, there are two traditional ways to collect
honeybee venom: electrical stimulation (venom collected
in this way is termed ESV) or manual (“reservoir dis-
rupting”) venom extraction directly from venom glands
(venom collected in this way is termed GV) [3,4]. While
ESV can extract venom without the need to sacrifice any
bees, GV extraction is at expense of the honeybee’s life.
It is empirically recognized that GV contains more bio-
chemical components, and it has thus been assumed it
provides a more abundant potent bioactive source [3]
than ESV. To address this hypothesis, the proteomes of
GV and ESV were compared qualitatively and quantita-
tively. A better knowledge of their proteins will aid in
the selection of more appropriate forms of honeybee
venom to be used as a pharmacological source.
Venom toxins are secretory proteins that undergo a
series of post-translational modifications (PTMs) once
released from the venom glands of the honeybee, suchas phosphorylation, glycosylation, and sulfation [21].
PTMs play a potential role in influencing IgE binding
capacity [22] and protein immunogenicity and antige-
nicity [23,24]. Phosphorylation is one of the most im-
portant PTMs [25]. Phosphorylation of snake venom
has the potential to alter proteolytic activity, coagulability,
and neurotoxicity of proteins [26]. In honeybee venom,
very few proteins, such as mellitin and icarapin, are known
to be phosphorylated [18], and phosphorylation is not well
characterized.
In this work we aim to better characterize honeybee
venom by examining the proteomic differences of venom
resulting from two different extraction techniques. By
using more comprehensive techniques, we can identify
previously overlooked proteins, and better understand
phosphorylation patterns in honeybee venom.
Results
1-DE analysis
More protein bands were detected in GV than in ESV
(Additional file 1: Figure S1). A total of 22 proteins were
identified in all 12 fractions, of which 21 were from GV
and 13 were from ESV (Additional file 2: Table S1). Of
the 22 total proteins, 12 proteins were commonly repre-
sented in the two forms of bee venom. Notably, de-
hydrogenase/reductase SDR family member 11-like (in
GV) was identified as novel in the honeybee venom.
Only five toxic proteins were found in significantly
higher abundance in GV than in ESV: Api m 7, Api m 8,
Api m 9, vitellogenin and PLA2-like. The other highly
abundant proteins in GV were non-toxic, and were mainly
associated with antioxidant activities, protein folding, and
molecular transporters. In ESV, however, all 8 highly
abundant proteins were toxic: Api m 3, Api m 5, Api m 6,
MRJP8, MRJP9, icarapin-like, hyaluronidase, and MCDP
(Additional file 3: Figure S2, panel A). The abundance of
melittin, phospholipase A-2, and apamin preproprotein
showed no significant differences between the two forms
of venom (Additional file 2: Table S1).
2-DE analysis
2-DE analysis resulted in 216 and 104 protein spots (Mr
19 kDa −88 kDa, pI 4.5-8.67) resolved in GV and ESV, re-
spectively (Additional file 4: Figure S3). Of these, 70 of the
216 spots in GV and 24 of the 104 protein spots in ESV al-
tered their abundance (> 1.5-fold, p < 0.05). Among those
which showed a greater than 1.5-fold abundance change,
53 of the 70 GV spots and 17 of the 24 ESV spots were
successfully identified corresponding to 24 non-redundant
proteins in GV and ESV (Additional file 5: Table S2). Five
non-redundant proteins were shared in the two forms of
bee venom (Additional file 4: Figure S3, red arrow), and
19 other proteins were specifically expressed in GV
(Additional file 4: Figure S3, blue arrow), but none of
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venom toxins had a higher abundance (dipeptidyl pep-
tidase IV precursor (Api m 5), venom allergen acid
phosphatase (Api m 3), icarapin-like, and phospholip-
ase A-2 (PLA2) (Additional file 3: Figure S2, panel B).
In GV, however, only two toxic proteins were abun-
dant: venom serine carboxypeptidase (Api m 7) and ar-
ginine kinase. The other 17 specifically detected proteins
in GV were involved in antioxidant systems, protein fold-
ing and molecular transporters, carbohydrate or energy
metabolism (Additional file 3: Figure S2, panel B). The
remaining unidentified differential protein spots could be
attributed to either their low abundance to produce
enough spectra or that the search scores in the databases
did not produce unambiguous results.
Shotgun analysis
Twenty proteins were identified in the shotgun analysis,
of which 14 proteins were found in both GV and ESV.
Five additional proteins were identified only in GV, and
one protein was identified only in ESV (Additional file 6:
Table S3). Noticeably, secapin, proactivator polypeptide,
danJ homolog subfamily B member 11-like and histone
H2B.3-like were specifically identified in the shotgun
approach.
Abundance quantification showed that 9 venom toxins
had higher abundance in ESV than in GV: MCDP, PLA2,
Api m 5, MRJP8 and 9, Api m 3, hyaluronidase, icarapin-
like, Api m 6 and LOC408666. Vitellogenin (Api m 12)
had higher abundance in GV than in ESV (Additional file
3: Figure S2, panel C). Five others (melittin, secapin,
PLA2-like, proactivator polypeptide isoform 1, dnaJ
homolog subfamily B member 11-like) showed no sig-
nificant difference between GV and ESV (Additional
file 6: Table S3). Similar to the above 1-DE and 2-DE
analysis, proteins identified in GV were also associated
with antioxidant activities, protein folding and molecu-
lar transporters (Additional file 3: Figure S2, panel C).
In total, 44 non-redundant proteins were identified in
the two forms of bee venom, 16 proteins were shared in
GV and ESV: 13 venom toxins and 3 non-toxins. In GV,
27 proteins were specifically expressed: 4 toxins and 23
non-toxins. In ESV, only toxin MCD peptide was specif-
ically expressed. Generally, 17 proteins were identified in
ESV and 43 proteins were identified in GV, respectively
(Table 1 and Figure 1).
Of the 39 differentially expressed proteins between GV
and ESV (Figure 2), 29 were more highly expressed in
GV: 6 venom toxins and 23 other non-toxin proteins asso-
ciated with antioxidant systems, carbohydrate or energy
metabolism, protein folding and molecular transporters.
In contrast, 10 proteins were more highly expressed in
ESV than GV: 9 venom toxins, and one non-toxin related
protein. The three other venom toxins such as melittin,secapin, apamin had no significant difference between GV
and ESV.
Phosphopeptide analysis
ESV contained 82% of venom toxins based on the above
analysis, and was, therefore used for the phosphorylation
analysis of honeybee venom. Currently, a total of 4 phos-
phopeptides corresponding to three venom toxins have
been identified (Table 2 and Figure 3): icarapin-like pre-
cursor was phosphorylated at S43 and S205; phospholip-
ase A-2 was phosphorylated at T145 and apamin
preproprotein was phosphorylated at T23.
Discussion
We used complementary proteomics approaches to gain
insight into the proteome differences of honey bee
venom extracted using two different methods (GV and
ESV) and to map the phosphorylation sites of the most
common used form of venom for therapeutic purposes.
Of the 44 proteins identified in both GV and ESV,
most of venom toxins were in higher abundance in
ESV than in GV. The most abundant proteins detected
in GV were mainly involved in protection of the venom
gland from tissue damage or in supporting glandular de-
velopment. This suggests that electrical stimulation could
generate a more pure venom as its contamination with
cellular proteins is much smaller than that of the manual
method. This method is also convenient for commercial
production and does not sacrifice the bees in the collec-
tion process. This is in sharp contrast with the manual
milking of bee venom (GV), in which the bee is sacrificed,
and the venom is contaminated by non-toxin proteins that
may leak from the gland tissue that is cut/disrupted dur-
ing venom collection. This provides a new scientific basis
for the use of ESV as a potential pharmacological source
over GV, taking into consideration both production effi-
ciency and honeybee welfare. Four novel phosphorylation
sites identified in three venom proteins may be involved
in specific elicitation of an immune response via recogni-
tion of antigenic determinants [18]. The identification of
two novel venom proteins significantly extends our in-
depth understanding of the biological nature of honeybee
venom.
More recently, Resende et al. (2013) [18] has used a
higher resolution of MS than our adopted MS for the
profiling of bee venom, and identified many new proteins
and three phosphorylation sites mapped to icarapin and
melittin. Using our gel-based and gel-free proteomics ap-
proaches, two novel proteins, SDR and histone H2B.3-like,
were identified, and phosphorylation of phospholipase
A-2, apamin preproprotein and S43 in icarapin-like
precursor were assigned as novel sites. This indicates
that the combined gel-based and gel-free proteomics
approaches are a robust protocol for the achievable
Table 1 Classification of identified proteins in honeybee venom manually extracted from venom gland and electrical













1-D E 2-DE Gel-free 1-DE 2-DE Gel-free
gi|5627 Phospholipase A-2 (Api m 1) Bee venom toxins Y 2, 57 √ √ √ √ √ √
gi|58585182 Hyaluronidase precursor (Api m 2) Y 2, 57 √ √ √ √
gi|66821891 Venom allergen acid phosphatase
(Api m 3)
N 2 √ √ √ √ √ √
gi|28201825 Melittin (Api m 4) Y 2, 57 √ √ √ √
gi|187281543 Venom dipeptidyl peptidase IV
precursor (Api m 5)
Y 2, 57 √ √ √ √ √ √
gi|94400907 Allergen Api m 6 precursor (Api m 6) Y 2, 57 √ √ √ √
gi|187281550 Venom carboxylesterase-6 precursor
(Api m 8)
Y 2, 57 √ √
gi|60115688 Icarapin-like precursor (Api m 10) Y 2, 57 √ √ √ √ √ √
gi|67010041 Major royal jelly protein 9 precursor
(Api m 11)
Y 2, 57 √ √ √ √
gi|58585070 Major royal jelly protein 8 precursor
(Api m 11)
Y 2, 57 √ √ √ √
gi|58585166 Apamin preproprotein Y 2, 57 √ √
gi|223850 Secapin N 5,38 √ √
gi|110758297 Phospholipase A2-like Y 2, 57 √ √ √ √
gi|1708948 Mast cell degranulating peptide Y 2, 57 √ √
gi|58585116 Venom serine protease 34 precursor
(Api m 7)
Y 2, 57 √ √
gi|226533687 Venom serine protease 34 precursor
Venom serine carboxypeptidase
precursor (Api m 9)
Y 2, 57 √
gi|58585146 Arginine kinase N 36 √
gi|58585104 Vitellogenin (Api m 12) Y 57 √ √
gi|380020933 Glutathione S-transferase-like isoform
1 (GstS1)
Antioxidant systems N 57 √
gi|58585086 Transferrin 1 precursor (Tsf1) Y 57 √
gi|110755367 Toll-like receptor 13-like isoform 1 (TLRs) Y 57 √
gi|66514614 Chitinase-like protein Idgf4-like Y 57 √
gi|283436152 Peroxiredoxin-like protein (Prx) N 57 √
gi|295849268 Superoxide dismutase 1 (Sod1) N 57 √
gi|22982210 Heat shock protein cognate 4 (Hsc) N 57 √
gi|149939403 Hexamerin N 57 √ √




Y 57 √ √
gi|335892796 Peptidyl-prolyl cis-trans isomerase
B precursor
Y 57 √
gi|328782499 Proactivator polypeptide isoform 1 Y 57 √ √
gi|328780884 Apolipophorins isoform 1 N 57 √ √
gi|328780886 Apolipophorins-like Y 57 √
gi|110749558 Histone H2B.3-like N 57 √
gi|66535784 Odorant binding protein 21 precursor
(Obp 21)
Y 57 √
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Table 1 Classification of identified proteins in honeybee venom manually extracted from venom gland and electrical
stimulation by gel-based and gel-free techniques (Continued)
gi|66515272 V-type proton ATPase catalytic





gi|328785025 ATP synthase subunit beta,
mitochondrial (ATPsyn-beta)
N 57 √
gi|328776580 Enolase-like (Eno) N 57 √
gi|66525576 Aldose reductase-like (AR) N 57 √
gi|328780312 Alcohol dehydrogenase [NADP+]
A-like (Adh)
N 57 √
gi|66506786 Malate dehydrogenase cytoplasmic-like (MDH1) N 57 √
gi|66550890 Phosphoglycerate mutase 2-like
(Pglym)
N 57 √
gi|328779578 Lysozyme c-1 Others 4 Y 57 √ √
gi|328783193 Dehydrogenase/reductase SDR family
member 11-like (SDR )
N 57 √ √
gi|328789531 Hypothetical protein LOC408666 Y 57 √ √ √ √
gi|48095525 Tubulin beta-1 chain N 57 √
All proteins are identified as Apis mellifera origin. Accession number is the unique number given to mark the entry of a protein in the database of NCBInr used to search against
in Mascot software. √ indicates the proteins identified by corresponding proteomics approaches such as 1-DE, 2-DE and shotgun. Y and N indicate whether a protein is a
secretory protein or not, which the evidence is given in source column.
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bee venom.
In order to effectively utilize venom in defense of their
community, the honeybee using its venom inflicts the in-
vader with the utmost suffering through systemic IgE-
mediated allergic reactions after insect stings. This could
result in potentially life-threatening and sometimes fatal
immune-mediated anaphylaxis. Our study has identified
all the 12 allergens (Api m 1–12) in the honeybee venom.
Melittin (Api m 4) is the major allergen responsible for
intense local pain [27] and can trigger the lysis of a
wide range of cells [28]. Phospholipase A-2 (Api m 1)Figure 1 Number comparison of the identified protein in
venom of A. m. ligustica manually collected from venom glands
(GV) and electrically stimulated (ESV). Venn diagram shows the
taxonomical distribution of the identified 44 proteins. Numbers in
the parenthesis indicate the amount of proteins ascribed to venom
toxins and non-toxins, respectively.is important for the specific IgE induction in sting victims
[9]. Hyaluronidase (Api m 2) facilitates the diffusion of
other venom constituents through the interstitial space
[29]. Api m 3, 5–12 are recognized as a strong IgE and T-
cell response to bee venom of the sting victim [30]. Except
for Api m 7–9 and melittin, the higher abundance of all
above allergens in ESV are thought to be a survival strat-
egy of the honeybee to effectively defend individuals and
the colonies they live in [31].
In addition, the identified other toxins, such as MCD
peptide, venom serine carboxypeptidases, venom serine
proteases, arginine kinase, apamin, and secapin, work as
enhancers for a massive release of histamine [32], deg-
radation of insect neurotransmitters [33], mediation of
immunity-related processes [34], phosphorylation of
venom proteins [16,35-37], and influencing the ner-
vous system as a neurotoxic polypeptide [38].
Although honeybee venom is mainly physiologically
effective for toxicological suffering in the sting victim,
the reported pharmacological applications are mainly
from the toxins. Melittin and phospholipase A-2 have
been reported to inhibit tumor cell proliferation and
thus have potential value for the cure of cancer [39,40],
and the attenuation of HIV-1 infectivity [10]. Hyaluroni-
dase can be used as an anesthetic, analgesic, anti-cancer
agent and also to help the spread of drugs in tissues
[41]. Dipeptidyl peptidase IV has functionally suppressed
peritoneal dissemination and progression of ovarian car-
cinoma and inhibits malignant phenotypes of prostate
cancer cells [42,43]. The MCD peptide has reported
anti-inflammatory activity at higher concentrations, which
can be used as a tool in studying secretory mechanisms
Figure 2 Quantitative comparisons of differentially abundant proteins in honeybee (A. m. ligustica) venom manually collected from the
venom gland (GV) and electrically stimulated (ESV). The ratio of the protein abundance is ESV to GV. The positive values indicate higher
protein abundance in ESV, negative values denote higher protein abundance in GV. The ratio is limited to 10, and error bar is standard deviation.
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proteins had either a higher abundance in ESV (phospho-
lipase A-2, hyaluronidase, the MCD peptide, and venom
dipeptidyl peptidase IV) or were found in equal abun-
dance in GV and ESV (melittin, apamin and secapin).
Therefore, the utilization of ESV as a potential pharmaco-
logical source is a more efficient and convenient choice asTable 2 Identification of phosphorylated sites on peptides in
Protein name Mass −10lgP Phosphorylation sit
Icarapin-like precursor, 33-46 1661.8752 39.63 S43
Icarapin-like precursor, 202-223 2485.0896 56.65 S205
Phospholipase A-2, 145-160 2169.0061 44.56 T145
Apamin preproprotein 23-40 2170.9033 30.85 T23
Protein name and mass of the identified proteins searched against the NCBInr data
peptide in the protein sequence. Phosphorylated amino acid is labeled with Sp. Site
protein sequence. No. of spectra means the number of the identified phosphopept
peptides are accepted when -10lgP > 20 (p < 0.01) as well as FDR <0.1%.a valuable source for the future development of novel hu-
man therapeutics than that of GV [45].
In GV, many non-venom toxic proteins were identified
even though manually milking of the venom from the
gland was performed carefully. The toxin component in
the venom of manual collection has significantly lower
content than venom from a honeybee’s natural sting.honeybee venom collected by electrical stimulation
e No. of spectra Z Site* Modified peptides and sites
2 2 33-46 R.KNVDTVLVLPS(+79.97)IER.D
2 2 202-223 R.SVES(+79.97)VEDFDNEIPKNQGDVLTA
1 4 145-160 Y.T(+79.97)VDKSKPKVYQWFDLR.K
2 4 23-40 V.T(+79.97)PVMPCNCKAPETALCAR.R
base in 2.5. Modified site is the position of the initial and final amino acids of
* is the position of the initial and final amino acids of the peptide in the
ides’s mass spectra. Z means the charge of identified phosphopeptide. The
Figure 3 (See legend on next page.)
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Figure 3 Tandem mass spectra of phosphorylated peptides from electrically stimulated venom of A. m. ligustica. The blue and red color
codes represent ions of b and y, respectively. The precursor ion marked as pre. Panel 1 and 2 are spectra of KNVDTVLVLPS(+79.97)IER
phosphorylated on S43 and SVES(+79.97)VEDFDNEIPKNQGDVLTA phosphorylated on S205 in icarapin-like precursor. Panel 3 is a spectrum of T
(+79.97)VDKSKPKVYQWFDLR that phosphorylated on T145 in phospholipase A-2. Panle 4 is spectrum of T(+79.97)PVMPCNCKAPETALCAR that
phosphorylated on T23 in apamin preproprotein.
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taminated by leaking when gland tissues were damaged.
They are involved in many pathways for the normal
functionality of venom glands to secrete venom toxins
and development, such as antioxidant systems, protein
folding, molecular transporters, carbohydrate and energy
metabolism. They might play an important role in pro-
tection of the secretory cells of the venom gland from
the harmful damage of toxins [16]. Although some of
the proteins were identified as putative secretory pro-
teins, we could not rule out that they are the remaining
trace amounts of bee venom toxin, since the reported
toxin accounts for >80% of venom content [5,18,38], this
requires further study to confirm if they are real toxin
proteins in bee venom.
Phosphorylation is a quite rapid biological reaction in
quick response to external stimulus and internal signals.
The phosphorylation site is recognized as an important
allergenic epitope, and the allergenicity of the proteins is
affected by a change in the epitope [46,47]. To fully exert
the toxic power towards protecting the honeybee colony,
the phosphorylation of venom toxin is probably to en-
hance the efficiency of local tissue damage, induction
of death in other insects and pain, and allergy and in-
flammation in higher organisms [4,48]. To this effect,
icarapin-like protein is suspected in evoking an immune
response after a bee sting through protein phosphoryl-
ation [49]. Phosphorylation of phospholipase A-2 may be
responsible for increasing its lysis activity [50]. Apamin is
an important neurotoxic polypeptide, and its phosphoryl-
ation may participate in the modulation of Ca2+-activated
K+channel [51,52] that acts on the central nervous system
[53]. The mapped S205 in Icarapin is the same as the re-
port of Ferreira Resende (2013) [18]. The other assigned
sites in phospholipase A-2 and Apamin and S43 in
icarapin-like precursor are novel.
Conclusions
Using complementary gel-based and gel-free proteomic
techniques, we have found that proteins in ESV are
mainly composed of toxin proteins and most of them
are highly abundant. Proteins identified in GV are
mainly those which have been contaminated by the
venom tissue damage during the milking process. ESV is
the better form to more efficiently utilize honeybee
venom as a potential pharmacological source, in terms
of obtaining it commercially and without the need tosacrifice each individual bee. The identification of two
novel proteins and three phosphorylation sites on venom
proteins provides key information to gain new insight
into the biochemical properties of honeybee venom.
Methods
Chemical reagents
The chemicals used for 1-DE, 2-DE and Formic acid
(FA) were purchased from Sigma (St. Louis, MO, USA)
except for Biolyte and immobilized pH gradient (IPG)
strips that were purchased from Bio-Rad (Hercules, CA,
USA). Dithiothreitol (DTT) and iodoacetamide (IAA)
were from Merck (Darmstadt, Germany). The modified
sequencing grade trypsin was from Roche (Mississauga,
ON, Canada). Ti4+-IMAC materials were kindly offered
by Dalian Institute of Chemical Physics. Trifluoroacetic acid
(TFA) and acetonitrile were from J.T.Baker (Phillipsburg,
NJ). Chemicals used for silver-staining were purchased
from Beijing Shiji Co. (Beijing, China).
Venom collection
The venom samples were collected from five colonies of
Italian honeybees (Apis mellifera ligustica) in the apiary
of The Institute of Apicultural Research, Chinese Acad-
emy of Agricultural Sciences in Beijing. For the GV har-
vested from honeybee workers, manual (or reservoir
disrupting) venom extraction was performed as follows:
100 guard bees were captured near the entrance of the
colony and anesthetized by chilling at −20°C. After-
wards, each individual was dissected, the sting apparatus
and the venom reservoirs were removed, and a filter
paper blot was used to prevent contamination by any
hemolymph that had stuck onto the outside. A capillary
tube was used to pierce the reservoir to collect the
venom from the gland followed by mixing with lysis
buffer (8 M urea, 2 M thiourea, 4% CHAPS, 20 mM
Tris-base, 30 mM DTT, proteinase inhibitor cocktail)
for immediate protein extraction. The venom collected
using the ESV method was collected by a device with a
mild electric shock through wires above the collecting
tray. The beehive lid and the cover cloth were taken
off and then a tray (sprayed with the proteinase and
phosphatase inhibitor cocktail before transfer to the
hives) was put on the hive top and it was assessed that
the steel wires were facing down. The wires were alter-
nately charged to a maximum of 3 volts. When shocked,
the bees stung the nylon taffeta under which was a glass
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and was scraped off with a knife. The collected venom
was kept at −80°C until use. Three independent biological
replicates were produced for the protein abundance quan-
titation in 1-DE, 2-De, and shotgun analyses. Protein
preparation was performed as described previously [54].
To do comparable quantitation between the two forms of
venom, the content of extracted protein was determined
[54] and equal amounts of protein sample were subjected
to 1-DE, 2-DE, and shotgun analyses. The protein sample
was divided into three parts for the following analysis.
One-Dimensional Gel Electrophoresis (1-DE)
1-DE was performed by the previously described proto-
col [55]. The first part of the venom protein sample
(6.7 μg/1 μl buffer) of GV and ESV was dissolved in the
above mentioned lysis buffer, 50 μg of protein sample
(7.5 μl) were mixed with a loading buffer (2.5 μl)
[62 mM Tris (pH 6.8), 10% (v/v) glycerol, 2.5% (w/v)
SDS, and 5% (v/v) 2-mercaptoethanol, pH 6.8] for the
subsequent separation. The gel was stained by MS com-
patible silver-staining method according to Han et al.
[55]. The entire lanes were cut into 12 fractions and
transferred to sterile microcentrifuge tubes, then washed
and subjected to in-gel tryptic digestion according to
Han et al. [55]. Briefly, The silver-stained gel slices were
excised and destained in a 200 μl solution (30 mmol/L
K3Fe(CN)6: 100 mmol/L Na2S2O3 = 1:1) until the gel
spots were transparent, then dried for 10 min with ACN
(100%). They were then further dried for 30 min using a
Speed-Vac system (RVC 2–18, Marin Christ, Germany).
The gel slices were reduced with 10 mM DTT for 1 hour
and alkylated with 50 mM iodoacetamide for 1 h in the
dark. Next, the trypsin solution (10 ng/μl) was added to
the dried gel slices then the samples were incubated for
14 h at 37°C. 5% TFA and 50% acetonitrile acid was used
to extract the peptide fragments from the tryptic digests.
Finally, the supernatant of each gel slice was concen-
trated to 20 μl using a Speed-Vac system for the subse-
quent MS analysis. Three replications were performed
for each gel lanes.
Two-Dimensional Gel Electrophoresis (2-DE)
2-DE was performed by a previously described protocol
[56]. 500 μg of the second part of the protein sample of
GV and ESV were dissolved in the lysis buffer, and then
the mixture (1 μl mixture/4 μl rehydration buffer) was
added into a rehydration buffer (8 M uera, 2% CHAPS,
0.001% bromophenol blue, 45 mM DTT, and 0.5% Bio-
lyte, pH 3–10) for the 2-DE runs. The gel staining was
accomplished by the same method as the 1-DE. Three
independent and reproducible 2-DE gel images from the
two venom samples were digitized with Image Scanner III
(GE Healthcare, Piscataway, NJ, USA), and the gel imageswere analyzed with Progenesis SameSpot (Version 4, Non-
linear Dynamic, UK) software. All gels were matched with
one of the selected reference gels. The following gel, pro-
tein spot calculation, and normalization were done as pre-
viously described [56]. Protein abundance was represented
as the means and standard deviations from the triplicate
experiments, and the statistical significance between the
two means was analyzed by one-way ANOVA (Samespot,
version 4, nonlinear Dynamics, UK) using a q-value
multiple test. Only spots statistically significant with at
least 2-fold changes and p < 0.05 were considered to
be differential protein spots. The q-value was used to
estimate false positive results that determine adjusted
p-values for each test.
MS/MS analysis
In-gel digestion was done following a previously published
protocol [55]. The digested protein spots were analyzed by
the LC-MS/MS system (QTOF G6520, Agilent Technolo-
gies, Santa Clara, CA), equipped with a microwell-plate
autosampler G1377D (maintained at 4°C), a capillary sam-
ple loading pump G1382A, a nano pump G2225A, and a
HPLC-Chip interface (Chip Cube G4240A). The LC-chip
(Agilent Technologies) used for analysis of 1-DE gel slices
was constituted of a Zorbax 300SB-C18 enrichment col-
umn (160 nL, 5 μm) and a Zorbax 300SB-C18 analytical
column (75 μm× 150 mm, 5 μm) (G4240-62010, Agilent
Technologies, Santa Clara, CA). Elution from the analyt-
ical column was performed by a binary solvent mixture
composed of water with 0.1% formic acid (solvent A) and
acetonitrile with 0.1% formic acid (solvent B). The follow-
ing gradient program was used: 3% to 8% solvent B for
1 min, 8% to 40% B for 79 min, 40% to 85% B for 30 min,
and 85% B for 2 min. The LC-chip used for analysis of the
2-DE protein spots was the same as that used for1-DE,
but the enrichment column was 40 nL. The following gra-
dient program was used: 3% to 8% solvent B for 1 min, 8%
to 40% B for 5 min, 40% to 85% B for 1 min, and 85% B
for 1 min. The mass spectrometric conditions of Han et al.
were followed [55].
Shotgun analysis
50 μg of the third part of GV and ESV samples was
digested in-solution as described by Han et al. [55]. Be-
fore the MS/MS run, a digested protein sample was sep-
arated using a PL-SCX (50 × 0.3 mm, 1000 Å, Agilent
Technologies, Santa Clara, CA) exchange media online.
The peptides were separated into seven fractions with
salt step of 5, 10, 20, 30, 50, 70, and 90 mM of
NH4HCO3 for the gradient elution. Each fraction was
analyzed online with LC-MS/MS system (QTOF G6520,
Agilent Technologies, Santa Clara, CA) using the same
mass spectrometric parameters as 1-DE, except the load-
ing flow rate was 0.3 μl/min, and the chip flow rate was
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to 3% solvent B for 5 min, 3% to 4% B for 2 min, 4% to 5%
B for 3 min, from 5% to 10% B for 5 min, 10% to 12% B
for 5 min, maintained 12% B for 5 min, 12% to 13% B for
5 min, maintained 13% B for 5 min, 13% to 20% B for
5 min, 20% to 50% B for 5 min, maintained 50% B for
5 min, from 50% to 85% B for 5 min, and 85% B for 5 min
(the concentration of solvent B (acetonitrile with 0.1% for-
mic acid) was achieved by mixing it with solvent A: water
with 0.1% formic acid.Protein identification
Tandem mass spectra were retrieved using MassHunter
software (version B.04, Agilent Technologies). The com-
bined mgf file of MS/MS data was generated by Distiller
(version 2.4, Matrix Science, UK) and searched against a
sequence database generated from the NCBInr protein
sequences of Apis mellifera (downloaded April, 2012,
version 4.5 of the honeybee genome) with a total of
72,672 sequences, expanded with sequences of Drosophila
melanogaster (downloaded April, 2012), Sacharomyces
cerevisiae (downloaded April, 2012), and a common re-
pository of adventitious proteins (cRAP, from The Global
Proteome Machine Organization, downloaded April, 2012).
MS/MS data were searched using in-house Mascot (version
2.4.0, Matrix Science, UK). Carbamidomethyl (C) and Oxi-
dation (M) were selected as fixed and variable modifica-
tions, respectively. Enzyme, trypsin; missed cleavages, 1;
peptide tolerance, 50 ppm; MS/MS tolerance, 0.05 Da.
The false discovery rate (FDR) for the shotgun and 1-DE
analyses was set at <1% when the decoy (reverse) sequences
were included. Protein identification was accepted if they
had >95% confidence and contained at least two unique
peptides. If a protein was identified on the basis of one pep-
tide for the shotgun and 1-DE analyses, protein identifica-
tion having theoretical probability of obtaining a false
positive was set at <1 in 1000, meaning that these peptides
must have a (false positive) Mascot expect value of ≤ 0.001.
The presence of an N-terminal secretion signal peptides of
the identified proteins was verified using the SignalP 4.1
Server (http://www.cbs.dtu.dk/services/SignalP/) [57]. The
D-cutoff for signal-TM networks was set to 0.35.Quantification of protein abundance
The protein abundance identified by 1-DE and shotgun
analyses was estimated by the exponentially modified
Protein Abundance Index (emPAI) [58], which was auto-
matically calculated by the MASCOT search engine. The
emPAI can be directly used for reporting approximate
protein abundance in a large-scale analysis [59]. The
comparative analysis of the protein abundance was per-
formed using the one-way ANOVA (SPSS statistics 17.0,
version 17.0.0, IBM) and Duncan’s multiple tests. Anerror probability of p < 0.05 was considered statistically
significant.
Phosphopeptide enrichment using Immobilized Metal
Affinity Column (IMAC)
Ti4+-IMAC material was prepared as described by Zhou
et.al [60]. Phosphopeptide enrichment using IMAC was
followed by Yu et.al with minor modification [61].
100 μl of 500 mM K2HPO4 was used to elute phospho-
peptide from Ti4+-IMAC using 30 min of agitation and
15 min of sonication and finally centrifugation at
15000 g for 5 min. The two rounds of supernatant
were collected as enriched phosphopeptides and lyoph-
ilized for further analysis.
The dissolved phosphopeptides in 35 μl of 0.1% FA
were subjected to MS analysis according the above shot-
gun analysis without using SCX pre-fraction.
The phosphopeptide MS data were searched against
PEAKS studio (version 6.0, Bioinformatics solutions Inc.,
Canada) and searched against the database in the same
manner as the above shotgun analysis with the following
parameters: carbamidomethylation (C) was selected as
the fixed and oxidation; (M) and phosphorylation (STY)
were selected as the variable modifications; taxonomy,
all entries; enzyme, trypsin; missed cleavages, 2; peptide
tolerance, ± 50 ppm; and MS/MS tolerance, ± 0.05 Da.
A fusion-decoy strategy was employed to control FDR of
protein, and peptide identification used the cutoff score
of >20 (−10 lgP) and FDR < 0.1%. Similar to unmodified
peptides, incorrect peptide spectrum matches (PSMs) of
modified peptides have an equal chance of being derived
from either the target or decoy database. The target/
decoy database approach is used to estimate the false
discovery rate for modified peptide identification. The
success of two consecutive b-or y-type site-determining
ions was required to assign a confident site [62].
Animal ethical use issues
Honey bees are not a regulated invertebrate. Therefore,
no ethical use approval is necessary.
Additional files
Additional file 1: Figure S1. Separation of honeybee (A. m. ligustica)
venoms manually extracted from the venom gland (GV) and electrical
stimulation (ESV) using one-dimensional gel electrophoresis. 50 μg of
protein sample are subjected to each gel lane with three replications in
each sample. The proteins are separated into 12 fractions (marked by red
boxes and labeled 1-12) and stained using a mass spectrometry compatible
silver-staining method. The molecular weight markers (M) are indicated on
the left. Proteins are identified by high-performance liquid chromatography
chip quadruple time-of-flight tandem mass spectrometry as described
in 2.3.3.
Additional file 2: Table S1. Identification and quantitation of proteins
in honeybee venom manually extracted from venom gland (GV) and
electrical stimulation (ESV) by 1-DE analysis.
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http://www.biomedcentral.com/1471-2164/14/766Additional file 3: Figure S2. Quantitative comparisons of differential
abundant proteins in honeybee (A. m. ligustica) venom manually
collected from venom glands (GV) and electrical stimulated (ESV). The
ratio of the protein abundance is ESV to GV. The positive values indicate
higher protein abundance in ESV, negative values denote higher protein
abundance in GV. The ratio is limited to 10, and error bar is standard
deviation. Panel A, B and C are comparison of protein abundance
analyzed by one-dimensional gel electrophoresis (1-DE), two-dimensional
gel electrophoresis (2-DE) and shotgun analysis, respectively.
Additional file 4: Figure S3. Separation of honeybee (A. m. ligustica)
venoms manually extracted from the venom gland (GV) and electrical
stimulation (ESV) using two-dimensional gel electrophoresis (2-DE).
500 μg of each sample are subjected to 2-DE and the proteins are
stained using a mass spectrometry compatible silver-staining method.
Number-labeled spots are cut out and subjected to tryptic digestion for
mass spectrometry analysis.
Additional file 5: Table S2. Identification of different abundant
proteins between honeybee venom manually extracted from venom
glands (GV) and electrical stimulation (ESV) by 2-DE analysis.
Additional file 6: Table S3. Identification and quantitation of protein in
honeybee venom manually extracted from venom gland (GV) and
electrical stimulation (ESV) by shotgun analysis.
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